Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Example vaccine vial in clinic © John Cairns
  • Primary analysis, part of pre-specified trial protocol, follows interim analysis on Monday 22 March
  • Data are consistent with interim analysis, and will form submission by AstraZeneca to US FDA
  • Vaccine 76% effective against symptomatic COVID-19, and 100% effective against severe or critical disease and hospitalisation

This primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis.

In addition, results were comparable across age groups, with vaccine efficacy of 85% in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100% efficacy.

Read the full story on the University of Oxford website.

Similar stories

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.